… We compared the proportion of patients diagnosed as having genital warts in the pre-vaccination
and vaccination periods by using rate ratios and determined summary rate ratios along …

… Vaccine efficacy studies found that among HPV… vaccine has nearly 100% protection against
genital warts associated with HPV6 and 11, and an efficacy of about 83% for all genital warts …

… The quadrivalent HPV vaccine against HPV types 6, 11, 16, and 18 has been shown to be
highly effective against not only high-grade genital lesions but also GWs. Genital warts have a …

… impact of the vaccination program on the number of in-patient treatments for genital warts. …
in the proportion of vaccine-eligible women diagnosed with genital warts at out-patient sexual …

… of genital warts if they were to occur. Our aim was to determine if the national HPV vaccination
programme has had a measurable impact on clinical presentations of genital warts at a …

… The other two serotypes, HPV6 and 11, are responsible for genital warts (GWs), … genital
warts reduction in countries with HPV vaccination programs including quadrivalent HPV vaccine …

… cervical cancer plus genital warts, or … of the vaccine, the effect of information framing (’cervical
cancer’ versus ’cervical cancer plus genital warts’) on intention to receive the HPV vaccine …

… the reduction of genital warts in the UK [27]. The nonavalent HPV vaccine is expected to give
at least the same level of protection against genital warts as the quadrivalent vaccine, as co-…

… genital warts among vaccinated women aged <21 years in 2013/2014 suggest that virtually
all genital warts are due to types 6 or 11 or other HPV types which the quadrivalent vaccine …

… genital warts, HPV vaccination … warts in periods before and after vaccination began. Our
primary group of interest was female Australian residents who were eligible for free vaccination, …